Nexvet Biopharma Public Limited Company (NASDAQ:NVET) was a big mover last session, as its shares rose over 9% on the day. The upside was driven by the presentation of expanded positive clinical data for ranevetmab and frunevetmab. This also led to far more shares changing hands than in a normal session. This continues the recent uptrend for the company, as the stock is now up over 46% in the past one month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday’s price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Nexvet Biopharma currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.
A better-ranked biomedical stock is ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) which sports a Zacks Rank #1 (Strong Buy).
Is NVET going up? Or down? Predict to see what others think: Up or Down
NEXVET BIOPHARM (NVET): Free Stock Analysis Report
ANI PHARMACEUT (ANIP): Free Stock Analysis Report
Original post
Zacks Investment Research